NCT00464893 - Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2013

Conditions

Gastric CancerGastric Adenocarcinoma

Interventions

DRUG

Catumaxomab

10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16

DRUG

catumaxomab

10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg

Trial Locations (4)

Innsbruck

Hamburg, Berlin, Heidelberg, Köln, Halle

Terrassa

Nottingham